SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe and broadly accessible therapies.
În prezent, investigat într-un studiu pivot de fază 2, CART-ddBCMA este terapia cu celule T Arcellx care utilizează noul liant sintetic al companiei, D-Domain. Kite și Arcellx vor promova și comercializa împreună activul CART-ddBCMA în SUA, iar Kite va comercializa produsul în afara SUA
Terapia cu celule T CAR se numără printre tratamentele inovatoare pentru anumite tipuri de cancere de sânge. Sunt peste 750 în curs de desfășurare studii clinice in Terapia cu celule T CAR în China În prezent. Pacienții care doresc să se înscrie se pot contacta CancerFax linia de asistență pentru pacienți pe WhatsApp + 91 96 1588 1588 sau e-mail la info@cancerfax.com.
Despre Arcellx
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory mielom multiplu (r/r MM) in a Phase 2 pivotal trial. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration.
Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, through two programs: a Phase 1 study of ACLX-001 for r/r MM, initiated in the second quarter of 2022; and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk sindrom mielodisplastic, initiated in the fourth quarter of 2022.
Despre Zmeu
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on cell therapy to treat and potentially cure cancer. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial supply, and commercial product manufacturing.
Despre Gilead Sciences
Gilead Sciences, Inc. este o companie biofarmaceutică care a urmărit și a realizat progrese în medicină de mai bine de trei decenii, cu scopul de a crea o lume mai sănătoasă pentru toți oamenii. Compania se angajează să promoveze medicamente inovatoare pentru prevenirea și tratarea bolilor care pun viața în pericol, inclusiv HIV, hepatita virală și cancerul. Gilead operează în peste 35 de țări din întreaga lume, cu sediul central în Foster City, California. Gilead Sciences a achiziționat Kite în 2017.
